Department of Geriatric Medicine, CHU Amiens-Picardie, Amiens, France.
Department of Urology and Transplantation, CHU Amiens-Picardie, Amiens, France; EPROAD Laboratory EA 4669, Picardie Jules Verne University, Amiens, France.
J Am Med Dir Assoc. 2022 Jun;23(6):992-997. doi: 10.1016/j.jamda.2021.09.023. Epub 2021 Oct 13.
In the context of improved medication management of older patients, we wished to evaluate the overprescription of potentially inappropriate drugs [α1-blockers and 5α-reductase inhibitors (5-ARI)] for benign prostate hyperplasia (BPH). These drugs are considered by geriatricians to increase the risk of falls and pharmacodynamic interactions, but these properties have not yet been proven.
This was a descriptive study of drug prescriptions in a geriatric academic center.
We included all patients older than 75 years who received a prescription for α1-blockers or 5-ARIs for 2 weeks in our hospital.
We evaluated the prevalence of the potentially inappropriate prescription of α1-blockers and 5-ARI in older people during hospitalization using a new tool consisting of an 8-item list of explicit indicators developed using the most recent summary of product characteristics (SmPC) and latest European Association of Urology (EAU) guidelines.
A population of 117 patients (≥75 years) was included in the study. The median age was 84.5 (±6.3) years. The average time since urological medication prescription was 1.2 ± 1.6 years. According to explicit criteria, 84 patients (71.8%) received at least 1 potentially inappropriate urologic medication, 77 (91.7%) related to α1-blockers. Patients with a potentially inappropriate prescription for α1-blockers and/or 5-ARIs more frequently had urological assessments (P = .026), more frequently showed pharmacological interactions, with the risk of orthostatic hypotension (P = .005) or arrhythmia (P = .028), and experienced more falls in their history (P = .043). The misuse group was associated with an increased risk of falls, with an odds ratio of 3.22 (P = .039, 95% confidence interval 1.08-10.2).
In our study, potentially inappropriate prescriptions for older individuals for BPH was close to 72% and mainly involved α1-blockers. Potentially inappropriate prescriptions for BPH were associated with a threefold higher frequency of falls.
在改善老年患者药物管理的背景下,我们评估了用于治疗良性前列腺增生(BPH)的潜在不适当药物(α1-受体阻滞剂和 5α-还原酶抑制剂(5-ARI))的过度处方情况。老年病医生认为这些药物会增加跌倒和药效学相互作用的风险,但这些特性尚未得到证实。
这是一项在老年医学学术中心进行的药物处方描述性研究。
我们纳入了所有在我院住院期间接受α1-受体阻滞剂或 5-ARI 处方治疗 2 周的 75 岁以上患者。
我们使用一种新工具评估了住院期间老年人潜在不适当的α1-受体阻滞剂和 5-ARI 处方的流行情况,该工具由根据最新药物特性摘要(SmPC)和最新欧洲泌尿外科学会(EAU)指南制定的 8 项明确指标清单组成。
共纳入 117 名(≥75 岁)患者。中位年龄为 84.5(±6.3)岁。距泌尿科药物处方的平均时间为 1.2±1.6 年。根据明确标准,84 名(71.8%)患者至少接受了一种潜在不适当的泌尿科药物治疗,其中 77 名(91.7%)与α1-受体阻滞剂有关。接受α1-受体阻滞剂和/或 5-ARI 潜在不适当处方的患者更频繁地进行泌尿科评估(P=0.026),更频繁地出现药物相互作用,体位性低血压风险增加(P=0.005)或心律失常(P=0.028),且既往跌倒史更多(P=0.043)。误用组与跌倒风险增加相关,优势比为 3.22(P=0.039,95%置信区间 1.08-10.2)。
在我们的研究中,用于治疗老年 BPH 的潜在不适当处方接近 72%,主要涉及α1-受体阻滞剂。BPH 的潜在不适当处方与跌倒频率增加三倍相关。